

FORM 7 MONTHLY PROGRESS REPORT

Name of Listed Issuer: AREV Nutrition Sciences Inc. ("AREV" or the "Issuer")

Trading Symbol: AREV

Number of Outstanding Listed Securities: 32,084,209

Date: February 11, 2018

Report on Business:

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

The Issuer, AREV Nutrition Sciences Inc. ("AREV"), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.

During the month of January 2018 AREV Nutrition Sciences Inc. was pleased to announce The Company is also pleased to announce that Chiron Capital Inc., a company directly controlled by Mike Withrow, has converted the second of two convertible debentures into units of the Company, each unit consisting of a common share of the Company and a common share warrant of the Company. The total principal amount of the convertible debentures exercised is \$300,000. The convertible debentures has been converted into units of the Company at a conversion price of \$0.05 per unit with a term ending September 16, 2018.

The conversion of this Convertible Debenture retires longterm debt of the Company. After converting the debenture, Chiron Capital Inc., has exercised 2,000,000 warrants at a price of \$0.05 per common share for a total cost of \$100,000.

If all of Mike Withrow's convertible securities were converted into common shares of the Company Mike Withrow would control 18,112,000 (42%) of a total of 43,342,800 fully diluted common shares of the Company.

During the month of January 2018 AREV Nutrition Sciences Inc. was pleased to announce a binding agreement (the "Acquisition Agreement") to acquire 100% of the issued and outstanding shares of We Grow BC Ltd. ("WGBC").

WGBC is a private company strategically located in Creston British Columbia in the heart of the Kootenay's, where BC grown marijuana originated, and holds a Cultivation License pursuant to the Access to Cannabis for Medical Purposes Regulations under Health Canada. The Company has scalable production facilities currently consisting of 100 acres of land with 100,000 square feet of indoor space of which 24,000 has been retrofitted for Phase 1 Cultivation.

The Acquisition Agreement provides for each shareholder of WGBC to receive 90,909 shares of AREV in exchange for each share of WGBC based on a \$50,000,000 valuation of WGBC. It is anticipated a total of 100,000,000 AREV shares will be issued at a deemed price of \$0.50 per AREV Share pursuant to the agreement.

AREV's intention is to enter into an amalgamation by plan of arrangement where the amalgamation shall take place between a wholly owned subsidiary of AREV and WGBC.

AREV intends to call a Special Annual General meeting in order to approve the transaction and to affix its board of directors to 7 members of which 4 will be designated by WGBC.

The deemed aggregate value of \$50,000,000 (\$50 million) attributable to such 100,000,000 AREV shares shall be supported by a valuation of WGBC. Also, it is understood that the AREV shares to be issued by AREV to the WGBC Shareholders may be subject to certain resale restrictions including escrow requirements under applicable securities law and policies of the Canadian Securities Exchange (the "CSE").

Both companies will have 5 business days from the date of execution of the Acquisition Agreement to provide the other party complete and commercially reasonable requests for due diligence.

The proposed acquisition of WGBC constitutes a fundamental change under the policies of the "CSE". and shall be subject to shareholder and CSE approval. Accordingly, trading of AREV shares has been halted pending acceptance of the Acquisition Agreement by the CSE and the acceptance and posting of regulatory filings in connection with the Acquisition Agreement under the Company's CSE profile.

2. Provide a general overview and discussion of the activities of management.

During the month of January 2018, management was mainly engaged in, forging ahead with cementing key relationships with industry players as well as interviewing key sales team members to join the AREV team. Management is working with WGBC to ensure all due diligence is conducted in a timely manner to allow for shareholder's to make an informed decision at a Special Meeting that will be called later this quarter.

In addition, management is working to further discussions with Canadian and International distributors with final agreements expected to conclude shortly.

- 2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None.

- 3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

- 4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

AREV announced a binding agreement (the "Acquisition Agreement") to acquire 100% of the issued and outstanding shares of We Grow BC Ltd. ("WGBC"). WGBC is not a related person and the Issuer will provide further details when they enter into a definitive agreement or the like.

- 6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

- 7. Describe any acquisitions by the Issuer dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None.

- 8. Describe the acquisition of new customers or loss of customers.**

None.

- 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

None.

- 10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None.

- 11. Report on any labour disputes and resolutions of those disputes if applicable.**

None.

- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

- 13. Provide details of any indebtedness incurred or repaid by the Issuer with the terms of such indebtedness together.**

None.

- 14. Provide details of any securities issued and options or warrants granted.**

None.

(1) State aggregate proceeds and intended allocation of proceeds.

None.

- 15. Provide details of any loans to or by Related Persons.**

None.

- 16. Provide details of any changes in directors, officers or committee members.**

None.

17. Discuss any trend which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Issuer's financial statements (the "YE Financial Statements") and corresponding management's discussion and analysis (the "YE MD&A") for the year-ended December 31, 2016. The Q4 Financial Statements and YE MD&A are both available under the Issuer's profile on SEDAR at www.sedar.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: February 11, 2018

Stephane Maher

Name of Director or Senior Officer



Signature

Chief Executive Officer and Director Official Capacity

| | | |
|---------------------------------------------|--------------------------------------|---------------------------------------|
| Issuer Details | For Month End | Date of Report |
| Name of Issuer AREV Nutrition Sciences Inc. | January, 2017 | 11/02/2018 |
| Issuer Address | | |
| Unit 2 – 9049 Shaughnessy Street | | |
| City/Province/Postal Code | Issuer Fax No. N/A | Issuer Telephone No. (608) 868 - 5013 |
| Vancouver, BC V6P 6R9 | | |
| Contact Name Denby Greenslade | Contact Position Corporate Secretary | Contact Telephone No. (604) 803-8439 |
| Contact Email Address | Web Site Address | |
| denby@arevnutrition.com | http://arevnutrition.com/ | |